Total Payments
$2,170
2024 Payments
$208.78
Companies
28
Transactions
102
Medicare Patients
25,783
Medicare Billing
$2.1M
Payment Breakdown by Category
Food & Beverage$2,100 (96.8%)
Education$69.95 (3.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,100 | 101 | 96.8% |
| Education | $69.95 | 1 | 3.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Galderma Laboratories, L.P. | $311.85 | 7 | $0 (2020) |
| PFIZER INC. | $164.94 | 10 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $161.35 | 8 | $0 (2024) |
| Janssen Biotech, Inc. | $156.79 | 6 | $0 (2019) |
| ABBVIE INC. | $145.21 | 7 | $0 (2024) |
| Amgen Inc. | $144.18 | 5 | $0 (2022) |
| Mayne Pharma Inc. | $126.74 | 4 | $0 (2018) |
| LEO Pharma Inc. | $102.98 | 6 | $0 (2020) |
| Lilly USA, LLC | $96.02 | 6 | $0 (2020) |
| UCB, Inc. | $89.68 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $208.78 | 9 | UCB, Inc. ($59.30) |
| 2023 | $67.97 | 4 | E.R. Squibb & Sons, L.L.C. ($29.85) |
| 2022 | $257.63 | 11 | Amgen Inc. ($129.61) |
| 2021 | $114.41 | 6 | Regeneron Healthcare Solutions, Inc. ($41.16) |
| 2020 | $152.62 | 9 | Galderma Laboratories, L.P. ($46.66) |
| 2019 | $436.65 | 23 | Janssen Biotech, Inc. ($83.98) |
| 2018 | $785.84 | 31 | Galderma Laboratories, L.P. ($249.50) |
| 2017 | $145.62 | 9 | PFIZER INC. ($31.96) |
All Payment Transactions
102 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: Immunology | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $14.89 | General |
| Category: Immunology | ||||||
| 09/25/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.91 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/28/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $24.15 | General |
| Category: IMMUNOLOGY | ||||||
| 08/06/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $23.08 | General |
| Category: Immunology | ||||||
| 04/04/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Winlevi (Drug), Absorica LD | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: Dermatology | ||||||
| 04/02/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $28.03 | General |
| Category: Dermatology | ||||||
| 03/29/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: Immunology | ||||||
| 02/06/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $32.75 | General |
| Category: IMMUNOLOGY | ||||||
| 05/16/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $14.09 | General |
| Category: Immunology | ||||||
| 04/12/2023 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $15.76 | General |
| Category: Immunology | ||||||
| 03/23/2023 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $22.41 | General |
| Category: Dermatology | ||||||
| 02/23/2023 | Arcutis Biotherapeutics, Inc. | — | Food and Beverage | In-kind items and services | $15.71 | General |
| 10/27/2022 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $17.99 | General |
| Category: Immunology | ||||||
| 10/06/2022 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: Immunology | ||||||
| 09/22/2022 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $17.05 | General |
| 09/08/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $20.10 | General |
| Category: Dermatology | ||||||
| 08/04/2022 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $7.23 | General |
| Category: Inflammation | ||||||
| 05/24/2022 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.91 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/19/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $22.32 | General |
| Category: Dermatology | ||||||
| 03/03/2022 | Sun Pharmaceutical Industries Inc. | Winlevi (Drug), Absorica LD | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: Dermatology | ||||||
| 02/14/2022 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $5.72 | General |
| Category: Inflammation | ||||||
| 01/20/2022 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $7.77 | General |
| Category: Inflammation | ||||||
| 01/19/2022 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $108.89 | General |
| Category: Inflammation | ||||||
| 12/22/2021 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.72 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 6,118 | 13,807 | $2.3M | $498,349 |
| 2022 | 28 | 6,890 | 15,350 | $1.4M | $593,543 |
| 2021 | 25 | 6,610 | 15,270 | $1.4M | $593,483 |
| 2020 | 27 | 6,165 | 13,051 | $1.2M | $451,072 |
Total Patients
25,783
Total Services
57,478
Medicare Billing
$2.1M
Procedure Codes
106
All Medicare Procedures & Services
106 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 1,136 | 1,696 | $446,410 | $97,028 | 21.7% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 462 | 663 | $326,855 | $79,376 | 24.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 657 | 844 | $250,122 | $55,970 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 407 | 561 | $209,179 | $49,635 | 23.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 1,011 | 1,384 | $271,052 | $45,428 | 16.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 483 | 586 | $194,075 | $44,321 | 22.8% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 924 | 6,641 | $129,569 | $32,261 | 24.9% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 65 | 76 | $67,537 | $17,169 | 25.4% |
| 12031 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.5 cm or less | Office | 2023 | 87 | 92 | $70,769 | $16,916 | 23.9% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 169 | 230 | $33,796 | $8,769 | 25.9% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 64 | 75 | $53,650 | $7,013 | 13.1% |
| 11901 | Injection into skin growth, more than 7 growths | Office | 2023 | 44 | 136 | $27,773 | $6,157 | 22.2% |
| 11401 | Removal of noncancer skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2023 | 88 | 97 | $44,255 | $5,792 | 13.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 77 | 77 | $25,103 | $5,267 | 21.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 122 | 136 | $22,379 | $5,205 | 23.3% |
| 17282 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 33 | 38 | $22,856 | $5,017 | 21.9% |
| 12042 | Intermediate repair of wound of neck, hands, feet, or genitals, 2.6-7.5 cm | Office | 2023 | 13 | 13 | $11,795 | $3,082 | 26.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $12,620 | $2,705 | 21.4% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2023 | 25 | 27 | $10,459 | $2,477 | 23.7% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 24 | 26 | $9,542 | $2,389 | 25.0% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 55 | 71 | $11,818 | $1,897 | 16.0% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 11 | 14 | $7,302 | $1,365 | 18.7% |
| 11622 | Removal of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2023 | 14 | 14 | $10,347 | $1,352 | 13.1% |
| 69100 | Biopsy of ear | Office | 2023 | 17 | 18 | $5,080 | $1,016 | 20.0% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 13 | 13 | $2,741 | $537.25 | 19.6% |
About Dr. Mary Evers, DO
Dr. Mary Evers, DO is a Dermatology healthcare provider based in Georgetown, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/02/2007. The National Provider Identifier (NPI) number assigned to this provider is 1053533026.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mary Evers, DO has received a total of $2,170 in payments from pharmaceutical and medical device companies, with $208.78 received in 2024. These payments were reported across 102 transactions from 28 companies. The most common payment nature is "Food and Beverage" ($2,100).
As a Medicare-enrolled provider, Evers has provided services to 25,783 Medicare beneficiaries, totaling 57,478 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 106 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Georgetown, TX
- Active Since 05/02/2007
- Last Updated 07/23/2019
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1053533026
Products in Payments
- EUCRISA (Drug) $164.94
- Otezla (Drug) $144.18
- DUPIXENT (Biological) $133.11
- DORYX (Drug) $126.74
- ENSTILAR (Drug) $102.98
- TALTZ (Drug) $96.02
- EPIDUO FORTE (Drug) $82.75
- NAFTIN (Drug) $80.88
- REMICADE (Biological) $73.42
- Tremfya (Drug) $69.95
- OPZELURA (Drug) $64.83
- Sotyktu (Drug) $62.73
- Bimzelx (Biological) $59.30
- SKYRIZI (Biological) $56.90
- COSENTYX (Biological) $53.32
- DUPIXENT DUPILUMAB INJECTION (Biological) $52.94
- SOOLANTRA (Drug) $49.24
- Humira (Biological) $44.95
- Winlevi (Drug) $36.57
- Veltin (Drug) $33.53
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Georgetown
Dr. Jean Elizze Charles, D.o, D.O
Dermatology — Payments: $126,992
Dermatology $126,992
Weilan Johnson, Md, MD
Dermatology — Payments: $7,240
Dermatology $7,240
Kevin Miller, Md, MD
Dermatology — Payments: $3,511
Dermatology $3,511
Dr. Eugen Stancut, Md, MD
Dermatology — Payments: $2,802
Dermatology $2,802
Dr. Mollie Jan, D.o, D.O
Dermatology — Payments: $2,495
Dermatology $2,495
Rachelle Naridze, M.d, M.D
Dermatology — Payments: $1,993
Dermatology $1,993